CytoMed Therapeutics is a company that focuses on translating its technologies into gamma delta (γδ) T cell- and natural killer (NK) cell-based immunotherapeutics for the treatment of cancers. It is also engaged in generating induced pluripotent stem cells (iPSCs) and developing them into cellular therapeutics.